Welcome to Marit Inngjerdingen's research group:

Lymphocytes and cancer immune surveillance

Marit Inngjerdingen<br>Group leader
Marit Inngjerdingen
Group leader


The group investigates mechanisms of how tumor cells evade and/or suppress the immune system, with a particular focus on NK cells and acute leukemia. NK cells contribute to protection from cancer development. Despite their anti-cancer activity, NK cell responses are often low in cancer patients. In patients with acute leukemia, low NK cell activity correlate with poor prognosis and high risk of relapse. Understanding the mechanisms behind deficient immune responses could aid development of improved immunetherapies directed at increasing the sensitivity towards malignant cells.


  • Longitudinal studies of NK cells in pediatric patients with ALL or AML in collaboration with the Department of Children, Oslo University Hospital, aiming at correlating NK cell responses and/or receptor repertoires with disease outcome.
  • In-depth mechanistic studies of how leukemia blasts evade and suppress the immune system using in vivo rat models of T-ALL and AML. Projects include tailoring NK cells for immunotherapy, and investigations on how soluble ligands and exosomes released from leukemic blasts affect NK cell tumor immune surveillance.
  • Characterization of intracellular signaling cascades in human T cells and NK cells.

Contact informations:
Marit Inngjerdingen, Department of Immunology, Oslo University Hospital (Rikshospitalet), P.O. Box 4950 Nydalen, N-0424 Oslo, Norway               
Tel: +47 23073769, Fax: +47 23073500, E-mail: mariti@medisin.uio.no